Form 4: Neurogene Inc. Director Acquires Stock Options

Robert Baffi, a director of Neurogene Inc., was granted stock options to purchase 7,700 shares of common stock on June 14, 2024.

Summary

• Robert Baffi, a director of Neurogene Inc., filed a Form 4 disclosing a transaction involving derivative securities.
• On June 14, 2024, Baffi acquired stock options representing the right to purchase 7,700 shares of Neurogene's common stock at an exercise price of $42.59.
• The options vest on the earlier of June 14, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon Baffi's continued service to the Issuer.
• Following the transaction, Baffi directly owns derivative securities representing 7,700 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard stock option grant to a director. It's a routine event and doesn't necessarily indicate positive or negative performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates that a director has been granted stock options, which is a common practice to incentivize management and align their interests with shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates